Abstract
4,5-dihydro-3(2H)pyridazinones such as CI-914, CI-930 and pimobendan along with tetrahydropyridopyridazine (endralazine) and perhydropyridazinodiazepine (cilazopril) have been used as potent positive inotropes, antihypertensives as well as platelet aggregation inhibitors. Accordingly, the present work involves the synthesis of 24 target compounds; 4,5-dihydro-3(2H)pyridazinones in addition to seven reported intermediates. The chemical structures of the new compounds were assigned by microanalysis, IR, 1H-NMR spectral analysis and some representatives by mass spectrometry. The positive inotropic effect of the final compounds and the intermediates 12a–12d as well as the reported intermediate compound 10 was determined in-vitro on isolated rabbit heart in comparison to digoxin. Data obtained revealed that twelve of the test compounds exhibited higher effective response than digoxin, nine compounds elicited comparable effects to digoxin and eight compounds were less active than digoxin. In addition, four compounds approved marked significant hypotensive effect better than that of the previously reported compound 10. Moreover, two compounds induced complete platelet aggregation inhibition. The last two compounds were also subjected to determination of their LD50 and they showed no signs of toxicity up to the dose level 300 mg/kg (i.p.), while the reported oral LD50 of digoxin is 17.78 mg/kg. Correlation of cardiotonic and hypotensive activities with structures of compounds was tried and pharmacophore models were computed to get useful insight onto the essential structural features required for inhibiting phosphodiesterase-III in the heart muscles and blood vessels.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdel-Rahman, M. S. H., Influence of antidepressants and quinidine on isolated pefused rabbit’s heart. M. Sci. Thesis, Assiut University, pp. 43–46, (1989).
Bristol, J. A., Sircar, I., Moos, W. H., Evans, D. B., and Weishaar, R. E., 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: Novel positive inotropic agents for the treatment of congestive heart failure. J. Med. Chem., 27, 1099–1101 (1984).
Calam, D., European Pharmacopoeia, (chairman of E.P. commission), The Fourth edn., Council of Europe, Strasbourg Cedex, France, pp. 916–917, (2001).
Chemical Computing Group Manual of Molecular Operating Environment (MOE), version 2007. 09., Inc. Montreal, Quebec, Canada (2005).
Erhardt, P. W., In Search of the Digitalis Replacement. J. Med. Chem., 30, 231–237 (1987).
Forest, M., Lahouratate, P., Martin, M., Nadler, G., Quiniou, M. J., and Zimmermann, R. G., A novel class of cardiotonic agents: Synthesis and biological evaluation of 5-substituted 3,6-dihydro-thiadiazi-2-ones with cyclic AMP phosphodiesterase inhibiting and myofibrillar calcium seneitizing properties. J. Med. Chem., 35, 163–172 (1992) and references therein.
Fujino, K., Sperelakio, N., and Solaro, R. J., Differential effects of d- and l-pimobendan on cardiac myofilament calcium sensitivity. J. Pharmacol. Exp. Ther., 247, 519–523 (1988).
Haikala, H. O., Honkanen, E. J., Lonnberg, K. K., Nore, P. T., Pystynen, J. J., Lurio, A. M., and Pippuri, A. K., Preparation of arylazinones for treatment of congestive heart failure. Eur. Pat. Appl. 383449, (1990), Through Chem. Abst. 114, 228967, 1991 and through internet.
Hansen, O., Interaction of cardiac glycosides with (Na+ + K+) Activated ATPase, A Biochemical link to Digitalis-Induced Inotropy. Pharmacol. Rev., 36, 143–160 (1984).
Hui, X., Fink, G. D., Chen, A., Watts, S., and Galligan, J. J., Nitric oxide independent effects of tempol on sympathetic nerve activity and blood pressure in normotensive rats. Am. J. Physiol. Heart Circ. Physiol., 281, H975–H980, (2001).
Mertens, A., Friebe, W., Müller-Beckmann, B., Kampe, W., Kling, L., and Von der saal, W., Nonsteroidal Cardiotonics, New 4,5-Dihydro-6-(1H-indol-5-yl)-pyridazin-3(2H)-ones and related compounds with positive inotropic activities. J. Med. Chem., 33, 2870–2875 (1990).
Moos, W. H., Humblet, C. C., Sircar, I., Rithner, C., Weishaar, R. E., Bristol, J. A., and McPhail, A. T., Cardiotonic agents: selective inhibitors of Adenosine 3′,5′-cyclic phosphate phosphodiesterase III. Elaboration of a five point model for positive inotropic activity. J. Med. Chem., 30, 1963–1972 (1987).
Murray, K. J., Eden, R. J., Dolan, J. S., Grimsditch, D. C., Stutchbury, C. A., Patel, B., Knowles, A., Worby, A., Lynham, J. A., and Coates, W. J., The effect of SK and F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function. Br. J. Pharmacol., 107, 463–470 (1992).
Okushiima, H., Narimatsu, A., Kobayashi, M., Furuya, R., Tsuda, K., and Kitada, Y. A novel class of cardiotonics, Synthesis and pharmacological properties of [4-(substituted-amino)-phenyl]pyridazinones and related derivatives. J. Med. Chem., 30, 1157–1161 (1987).
O’Neil, M. J., Merck Index Encyclopedia of Chemicals, Drugs and Biologicals, Heckelman, P. E., Koch, C. B., Roman, K. J., Kenny, C. M., and D’Arecea, M. R. (ed.), Fourteenth edn., Merck and Co., Inc., U.S.A., pp. 378, 610 and 1281, (2006).
Roche/Hitachi “Material Safety Data Sheet Roche Diagnostics”, TDM, Mira, Through Internet.
Rüegg, J. C., Effects of new inotropic agents on Ca++ sensitivity of contractile proteins.[Miscellaneous]. Circ., 73(suppl. III), III-78–III-8 (1986).
Rüegg, J. C., Pfitzer, G., Eubler, D., and Zeugner, C., Effect on contractility of skinned fibres from mammalian heart and smooth muscle by a new benzimidazole derivative, 4,5-Dihydro-6-[2-(4-methoxyphenyl]-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone. Arzenium Forsch./Drug Res., 34, 1736–1738 (1984).
Sircar, I., Duell, B. L., Bobowski, G., Bristol, J. A., and Evans, D. B., Synthesis and Structure activity Relationship of 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: A new class of positive inotropic agents. J. Med. Chem., 28, 1405–1413 (1985).
Sircar, I., Steffen, R. P., Bobowski, G., Burke, S. E., Newton, R. S., Weishaar, R. E., Bristol, J. A., and Evans, D. B., Synthesis and Biological Evaluation of a series of 4,5-Dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3(2H)-pyridazinones: A novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. J. Med. Chem., 32, 342–350 (1989).
Sweetman, S. C. (ed.), Martindale, The Complete Drug Reference (thirty-third edn.). The Pharmaceutical Press, London, pp. 955.3, 885.1 and 858.1, (2002).
Thyes, M., Lehmann, H. D., Gries, J., König, H., Kretzschmer, R., Kunze, J., Lebkücher, R., and Lenke, D., 6-Aryl-4,5-dihydro-3(2H)-pyridazinones: A new class of compounds with platelet aggregation inhibiting and hypotensive activities. J. Med. Chem., 26, 800–807 (1983).
Von Meel, J. C. A., Cardiovascular Effects of the positive inotropic agents pimobendan and sulmazole in vivo. Arzenium Forsch./Drug Res., 35, 284 (1985).
Weishaar, R. E., Quade, M., Schenden, J. A., Boyd, D. K., and Evans, D. B., Studies aimed at elucidating the mechanism of action of CI-914, a new cardiotonic agent. Eur. J. Pharmacol., 119, 205–215 (1985).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amin, E.N., Abdel-Alim, AA.M., Abdel-Moty, S.G. et al. Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities. Arch. Pharm. Res. 33, 25–46 (2010). https://doi.org/10.1007/s12272-010-2222-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-010-2222-x